Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737265 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT04737265 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 108 participants.
The verdict
NCT04737265, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
Interventions
- OTHER Biomarker Guided Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04737265
The ClinicalTrials.gov registry entry for NCT04737265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biomarker Guided Intervention is the first listed.
NCT04737265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04737265 about?
NCT04737265 is a clinical study titled "Pilot Study of an NTproBNP Guided Strategy of Cardioprotection". Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
What is the current status of trial NCT04737265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2021-03-18. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT04737265?
The interventions under investigation include: Biomarker Guided Intervention (OTHER).
Who is sponsoring clinical trial NCT04737265?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.